Computer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challenges
Barbara Wiśniowska1, Aleksander Mendyk, Kamil Fijorek
1Unit of Pharmacoepidemiology and Pharmacoeconomics, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9 Street, 30-688 Kraków, Poland.
Summary
Computer modeling and simulations are poised to enhance cardiac safety testing by integrating data. Further research is needed to address data sources, drug concentrations, and clinical validation for accurate arrhythmia risk assessment.
Area of Science:
- Pharmacology
- Computational Biology
- Toxicology
Background:
- Computer modeling and simulations are increasingly recognized for their potential in comprehensive cardiac safety testing.
- Their primary role involves integrating and interpreting existing data for drug safety evaluation.
Purpose of the Study:
- To identify and discuss unresolved issues and questions regarding the application of computer models in cardiac safety assessment.
- To highlight areas requiring further investigation for the effective utilization of these models.
Main Methods:
- Review of data sources for model development, including in vitro studies and quantitative structure-activity relationship (QSAR) models.
- Consideration of pharmacokinetic factors, such as active drug concentrations and their assessment points.
- Analysis of pharmacodynamic complexities, including multiple drug interactions and effects on ion channels.
Main Results:
- Identified key challenges in data integration, pharmacokinetic assessment, and pharmacodynamic modeling for cardiac safety.
- Emphasized the necessity of validating models against clinical data, considering physiological, anatomical, and genetic variability.
Conclusions:
- Mathematical models hold significant promise for cardiac safety assessment but require resolution of several critical issues.
- Further research and validation are essential to fully leverage computational approaches for predicting drug-induced arrhythmias.
Related Concept Videos
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
127
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
127
01:24Drug Toxicity: Risk factors
229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
498
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
498
01:25Dysrhythmias VI: Management of Dysrhythmias
597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K